In fiscal 2025, which ended Dec 31, 2025, Teva Pharmaceutical Industries Limited reported revenue of $17.3 billion, up 4.3% from the year before. Net income was $1.4 billion, a profit margin of 8.2%. Operating income came to $2.2 billion, an operating margin of 12.5%. Diluted earnings per share were $1.21. Over the twelve months ended Sep 30, 2026, revenue was $17.2 billion and net income was $506.0 million. Across the 10 fiscal years shown, revenue shrank from $20.3 billion in fiscal 2012 to $17.3 billion in fiscal 2025, about 1.8% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2013
Dec 31, 2013
|
FY 2012
Dec 31, 2012
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17,230
+2.7%
|
17,258
+4.3%
|
16,544
+4.4%
|
15,846
+6.2%
|
14,925
-6.0%
|
15,878
-4.7%
|
16,659
-1.4%
|
16,887
-7.6%
|
18,271
|
20,314
-0.0%
|
20,317
+10.9%
|
| Cost of revenue |
8,010
-4.3%
|
8,320
-1.9%
|
8,481
+3.4%
|
8,200
+3.1%
|
7,952
-4.0%
|
8,284
-7.3%
|
8,933
-4.5%
|
9,351
-6.3%
|
9,975
|
9,607
-0.6%
|
9,665
+9.9%
|
| Gross profit |
9,221
+9.7%
|
8,938
+10.8%
|
8,064
+5.5%
|
7,645
+9.6%
|
6,973
-8.2%
|
7,594
-1.7%
|
7,726
+2.5%
|
7,537
-9.1%
|
8,296
|
10,707
+0.5%
|
10,652
+11.9%
|
| Research and development |
—
|
—
|
—
|
—
|
98
|
—
|
—
|
—
|
114
|
5
|
—
|
| Selling, general and administrative |
4,161
+9.4%
|
3,973
+7.3%
|
3,702
+5.8%
|
3,498
+1.5%
|
3,445
-2.4%
|
3,528
-3.9%
|
3,671
-3.5%
|
3,806
-9.7%
|
4,214
|
5,319
+3.9%
|
5,117
+16.0%
|
| Other operating income (expense) |
93
+504.3%
|
-18
-228.6%
|
14
-71.4%
|
49
-54.2%
|
107
+9.2%
|
98
+145.0%
|
40
-47.4%
|
76
|
—
|
—
|
—
|
| Restructuring and impairment |
150
-31.2%
|
225
+204.1%
|
74
-33.3%
|
111
-24.0%
|
146
+9.8%
|
133
+10.8%
|
120
-39.7%
|
199
-59.2%
|
488
|
201
-9.0%
|
221
+15.1%
|
| Operating income |
1,435
-21.5%
|
2,157
+811.9%
|
-303
-170.0%
|
433
+119.7%
|
-2,197
-228.0%
|
1,716
+148.0%
|
-3,572
-706.3%
|
-443
+72.9%
|
-1,637
|
1,649
-25.2%
|
2,205
-29.1%
|
| Other income (expense) |
-1,074
-15.2%
|
-934
+4.8%
|
-981
+7.2%
|
-1,057
-9.4%
|
-966
+8.7%
|
-1,058
-26.9%
|
-834
-1.5%
|
-822
+14.3%
|
-959
|
-399
-3.4%
|
-386
-152.3%
|
| Pretax income |
362
-59.6%
|
1,223
+195.2%
|
-1,284
-105.8%
|
-624
+80.3%
|
-3,163
-580.7%
|
658
+114.9%
|
-4,406
-248.3%
|
-1,265
+51.3%
|
-2,596
|
1,250
-31.3%
|
1,819
-38.5%
|
| Income tax |
-136
-157.1%
|
-180
-126.6%
|
676
+9757.1%
|
-7
+98.9%
|
-643
-404.7%
|
211
+225.6%
|
-168
+39.6%
|
-278
-42.6%
|
-195
|
-43
+68.6%
|
-137
-207.9%
|
| Net income |
506
-29.0%
|
1,410
+186.0%
|
-1,639
-193.2%
|
-559
+77.1%
|
-2,446
-686.6%
|
417
+110.5%
|
-3,990
-299.4%
|
-999
+53.5%
|
-2,150
|
1,269
-35.4%
|
1,963
-28.9%
|
| Basic EPS |
0.44
-30.1%
|
1.23
+184.8%
|
-1.45
-190.0%
|
-0.50
+77.3%
|
-2.20
-678.9%
|
0.38
+110.4%
|
-3.64
-300.0%
|
-0.91
+61.3%
|
-2.35
|
1.49
-33.8%
|
2.25
-27.4%
|
| Diluted EPS |
0.43
-30.5%
|
1.21
+183.4%
|
-1.45
-190.0%
|
-0.50
+77.3%
|
-2.20
-678.9%
|
0.38
+110.4%
|
-3.64
-300.0%
|
-0.91
+61.3%
|
-2.35
|
1.49
-33.8%
|
2.25
-27.2%
|
| Weighted average shares, basic |
1,158
+1.5%
|
1,145
+1.2%
|
1,131
+1.1%
|
1,119
+0.8%
|
1,110
+0.7%
|
1,102
+0.6%
|
1,095
+0.4%
|
1,091
+6.9%
|
1,021
|
849
-2.6%
|
872
-2.0%
|
| Weighted average shares, diluted |
1,178
+2.1%
|
1,163
+2.8%
|
1,131
+1.1%
|
1,119
+0.8%
|
1,110
+0.3%
|
1,107
+1.1%
|
1,095
+0.4%
|
1,091
+6.9%
|
1,021
|
850
-2.6%
|
873
-2.2%
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
1,002
-5.4%
|
1,059
-8.2%
|
1,153
-11.9%
|
1,308
-1.7%
|
1,330
-14.6%
|
1,557
-9.6%
|
1,722
-6.5%
|
1,842
|
1,642
-3.9%
|
1,708
+59.8%
|
| EBITDA |
—
|
3,159
+317.9%
|
756
-52.3%
|
1,586
+278.4%
|
-889
-129.2%
|
3,046
+251.2%
|
-2,015
-257.5%
|
1,279
+523.9%
|
205
|
3,291
-15.9%
|
3,913
-6.3%
|
| Interest coverage |
—
|
2.35x
|
-0.30x
|
0.42x
|
-2.36x
|
1.93x
|
-3.96x
|
-0.54x
|
-1.78x
|
5.25x
|
6.21x
|
| Margins | |||||||||||
| Gross margin |
53.52%
|
51.79%
|
48.74%
|
48.25%
|
46.72%
|
47.83%
|
46.38%
|
44.63%
|
45.41%
|
52.71%
|
52.43%
|
| Operating margin |
8.33%
|
12.50%
|
-1.83%
|
2.73%
|
-14.72%
|
10.81%
|
-21.44%
|
-2.62%
|
-8.96%
|
8.12%
|
10.85%
|
| Pretax margin |
2.10%
|
7.09%
|
-7.76%
|
-3.94%
|
-21.19%
|
4.14%
|
-26.45%
|
-7.49%
|
-14.21%
|
6.15%
|
8.95%
|
| Profit margin |
2.94%
|
8.17%
|
-9.91%
|
-3.53%
|
-16.39%
|
2.63%
|
-23.95%
|
-5.92%
|
-11.77%
|
6.25%
|
9.66%
|
| EBITDA margin |
—
|
18.30%
|
4.57%
|
10.01%
|
-5.96%
|
19.18%
|
-12.10%
|
7.57%
|
1.12%
|
16.20%
|
19.26%
|
| Effective tax rate |
-37.57%
|
-14.72%
|
—
|
—
|
—
|
32.07%
|
—
|
—
|
—
|
-3.44%
|
-7.53%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TEVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Large accelerated filer
- SEC CIK
- 818686
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED (until Jan 16, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.